Ben Comer

Most Recent Articles by Ben Comer

Forest Labs to acquire Clinical Data, add reps for launch

Forest Labs will acquire Clinical Data for $1.2 billion, and expand its primary care sales forces in preparation for the launch of Viibryd (vilazodone HCI), executives said in a conference call.

Savient focusing on reimbursement

Savient Pharmaceuticals launched Krystexxa, an orphan drug for chronic gout, and deployed a mix of sales reps, education specialists and business managers to help expedite reimbursement from payers.

Ex-GSK marketer unveils migraine consumer site

Health Union, an online health information and social media company, announced the launch of its first website --Migraine.com--intended to foster "interactions about health conditions between and among patients, caregivers, professionals and providers."

Roche maintained DTC spending on Boniva, while competitors cut back

Roche maintained DTC spending on Boniva, while competitors cut back

Sally Field's winsome smile may have helped to curb declining sales of Roche's Boniva in 2010, but it didn't carry the drug past Warner Chilcott's Actonel, despite a substantially higher DTC spend.

Savient focuses on reimbursement for Krystexxa launch

Savient focuses on reimbursement for Krystexxa launch

Savient Pharmaceuticals launched Krystexxa (pegloticase), an orphan drug for chronic gout, on Monday, and deployed a mix of sales reps, education specialists and business managers to help expedite reimbursement from payers, executives said on a conference call.

More Articles by Ben Comer


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.